Drugs / sacubitril/valsartan
sacubitril/valsartan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02887183 | Oct 2016 → Oct 2018 | heart failure | Novartis Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-03-31 | Novartis Pharmaceuticals | Regulatory Novartis Entresto receives positive CHMP opinion for pediatric heart failure novartis.com ↗ |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-03-31 | Novartis Pharmaceuticals | Novartis Entresto receives positive CHMP opinion for pediatric heart failure novartis.com ↗ |
| 2020-03-02 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka enters into co-promotion agreement for angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 in Japan otsuka.co.jp ↗ |
| 2018-08-25 | Novartis Pharmaceuticals | Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode novartis.com ↗ |
| 2015-07-07 | Novartis Pharmaceuticals | Novartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization novartis.com ↗ |
| 2015-02-13 | Novartis Pharmaceuticals | Novartis' heart failure medicine LCZ696 granted FDA priority review novartis.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sacubitril/valsartan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02887183 ↗ |
| Known as | LCZ696 | “LCZ696 (sacubitril/valsartan) was supplied as unscored, ovaloid, film-coated oral tablets in the strengths of 24/26 mg, 49/51 mg, 97/103 mg to be taken twice daily (bid)” NCT02887183 ↗ |
| Known as | S/V | “Sacubitril/valsartan (S/V) treatment is associated with reverse cardiac remodeling and reductions in biomarkers reflecting ventricular wall stress and myocardial injury” PMID 33998243 ↗ May 2021 |
| Known as | Sac/Val | “sacubitril/valsartan (Sac/Val) improves left ventricular ejection fraction (LVEF) in heart failure (HF) with reduced ejection fraction regardless of previous treatments.” PMID 36599549 ↗ Nov 2022 |
| Action | Inhibit | “Through inhibition of neprilysin, Sac/Val may increase BNP concentrations.” PMID 35115085 ↗ Jan 2022 |
| Route | Oral | “film-coated oral tablets” NCT02887183 ↗ |